☰

Aaron Lim - Publications

Affiliations: 
2016-2021 Cancer Biology Vanderbilt University, Nashville, TN 
Tree Info Similar researchers PubMed Report error

5 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Lim AR, Vincent BG, Weaver AM, Rathmell WK. Sunitinib and Axitinib increase secretion and glycolytic activity of small extracellular vesicles in renal cell carcinoma. Cancer Gene Therapy. PMID 34088993 DOI: 10.1038/s41417-021-00345-1  0.482
2021 Shiuan E, Reddy A, Dudzinski SO, Lim AR, Sugiura A, Hongo R, Young K, Liu XD, Smith CC, O'Neal J, Dahlman KB, McAlister R, Chen B, Ruma K, Roscoe N, et al. Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. Cancers. 13. PMID 33806963 DOI: 10.3390/cancers13061475  0.439
2020 Lim AR, Rathmell WK, Rathmell JC. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. Elife. 9. PMID 32367803 DOI: 10.7554/Elife.55185  0.46
2019 Terzo EA, Lim AR, Chytil A, Chiang YC, Farmer L, Gessner KH, Walker CL, Jansen VM, Rathmell WK. Correction: loss sensitizes cells to PI3Kβ and AKT inhibition. Oncotarget. 10: 6391-6392. PMID 31695846 DOI: 10.18632/Oncotarget.27288  0.429
2019 Terzo EA, Lim AR, Chytil A, Chiang YC, Farmer L, Gessner KH, Walker CL, Jansen VM, Rathmell WK. loss sensitizes cells to PI3Kβ and AKT inhibition. Oncotarget. 10: 647-659. PMID 30774762 DOI: 10.18632/Oncotarget.26567  0.5
Show low-probability matches.